S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:VERU

Veru News Headlines

$13.38
-0.91 (-6.37%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$12.66
$14.21
50-Day Range
$4.35
$15.60
52-Week Range
$4.34
$17.50
Volume
11.55 million shs
Average Volume
24.79 million shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.57
Get Veru News Delivered to You Automatically

Sign up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Veru Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VERU
News Sentiment

0.18

0.30

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VERU Articles
This Week

29

6

VERU Articles
Average Week



Veru (NASDAQ:VERU) News Headlines Today

SourceHeadline
marketbeat.com logoBrookline Capital Acquisition Increases Veru (NASDAQ:VERU) Price Target to $31.00
marketbeat.com - May 18 at 3:11 PM
MarketBeat logoBrookline Capital Management Increases Veru (NASDAQ:VERU) Price Target to $31.00
americanbankingnews.com - May 20 at 5:25 AM
MarketBeat logoVeru (NASDAQ:VERU) Shares Gap Up After Analyst Upgrade
americanbankingnews.com - May 20 at 4:28 AM
MarketBeat logoVeru (NASDAQ:VERU) PT Raised to $31.00 at Brookline Capital Acquisition
americanbankingnews.com - May 20 at 3:49 AM
benzinga.com logoVeru To Present At H.C. Wainwright Global Investment Conference On May 24th 2022 - Benzinga - Benzinga
benzinga.com - May 19 at 9:58 AM
nasdaq.com logoCatch Fast-Moving Veru Stock as Covid-19 Drug Results Show Promise - Nasdaq
nasdaq.com - May 19 at 4:51 AM
seekingalpha.com logoVeru Inc. Still Has Serious Growth To Realize - Seeking Alpha
seekingalpha.com - May 19 at 4:51 AM
globenewswire.com logoVeru to Present at the HC Wainwright Global Investment Conference on May 24th 2022 - GlobeNewswire
globenewswire.com - May 18 at 11:51 PM
finance.yahoo.com logoVeru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 Patients - Yahoo Finance
finance.yahoo.com - May 18 at 6:50 PM
finance.yahoo.com logoVeru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 Patients
finance.yahoo.com - May 18 at 6:50 PM
investorplace.com logoVERU Stock Alert: 6 Things to Know as Veru Appoints a New Executive
investorplace.com - May 18 at 11:02 AM
benzinga.com logoSo What's Up With Veru Shares Rising Today? - Benzinga - Benzinga
benzinga.com - May 18 at 2:55 AM
investorplace.com logoCatch Fast-Moving Veru Stock as Covid-19 Drug Results Show Promise - InvestorPlace
investorplace.com - May 17 at 4:54 PM
seekingalpha.com logoVeru: Where Big Pharma Failed To Tread - Seeking Alpha
seekingalpha.com - May 17 at 4:54 PM
investorplace.com logoCatch Fast-Moving Veru Stock as Covid-19 Drug Results Show Promise
investorplace.com - May 17 at 1:02 PM
finance.yahoo.com logoVeru to Present at the H.C. Wainwright Global Investment Conference on May 24th 2022 - Yahoo Finance
finance.yahoo.com - May 17 at 9:01 AM
finance.yahoo.com logoVeru to Present at the H.C. Wainwright Global Investment Conference on May 24th 2022
finance.yahoo.com - May 17 at 9:01 AM
MarketBeat logoVeru (NASDAQ:VERU) Price Target Raised to $55.00 at Jefferies Financial Group
americanbankingnews.com - May 17 at 2:11 AM
benzinga.com logoHow Is The Market Feeling About Veru? - Benzinga - Benzinga
benzinga.com - May 16 at 6:00 PM
finance.yahoo.com logoVeru: EUA for Covid-19 Treatment Could Be Granted by Q3, Says Oppenheimer
finance.yahoo.com - May 16 at 6:00 PM
benzinga.com logoThinking about buying stock in Borr Drilling, Desktop Metal, Veru, Unity Software, or Redbox Entertainmen - Benzinga
benzinga.com - May 15 at 12:18 PM
MarketBeat logoVeru (NASDAQ:VERU) Rating Reiterated by Cantor Fitzgerald
americanbankingnews.com - May 15 at 1:34 AM
benzinga.com logoVeru Shares Spike, Jefferies Reiterates Buy Rating And Raises PT To $55 - Benzinga - Benzinga
benzinga.com - May 13 at 2:27 PM
globenewswire.com logoBioMed Stocks On the Move: Nova Mentis, PolarityTE, Veru, and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, Novel Therapeutics for Oncology, COVID, Glaucoma, and Autism - GlobeNewswire
globenewswire.com - May 13 at 2:27 PM
seekingalpha.com logoVERU stock surges as Jefferies raises target citing COVID-19 candidate (NASDAQ:VERU) - Seeking Alpha
seekingalpha.com - May 13 at 2:27 PM
finance.yahoo.com logoBioMed Stocks On the Move: Nova Mentis, PolarityTE, Veru, and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, Novel Therapeutics for Oncology, COVID, Glaucoma, and Autism
finance.yahoo.com - May 13 at 2:27 PM
finance.yahoo.com logoVeru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?
finance.yahoo.com - May 13 at 2:27 PM
seekingalpha.com logoVeru Inc.'s (VERU) CEO Mitchell Steiner on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 13 at 2:49 AM
seekingalpha.com logoVeru GAAP EPS of -$0.18 misses by $0.06, revenue of $13.03M misses by $2.23M (NASDAQ:VERU) - Seeking Alpha
seekingalpha.com - May 12 at 2:54 PM
nasdaq.com logoHealth Care Sector Update for 05/12/2022: ABC, WBA, VERU, SHCR, XLV, IBB - Nasdaq
nasdaq.com - May 12 at 9:53 AM
seekingalpha.com logoVeru Q2 2022 Earnings Preview (NASDAQ:VERU) - Seeking Alpha
seekingalpha.com - May 11 at 7:25 PM
marketwatch.com logoVeru stock soars after FDA agrees COVID-19 treatment can be submitted for EUA application - MarketWatch
marketwatch.com - May 11 at 7:25 PM
benzinga.com logoVeru shares are trading higher after the company announced that in a Pre-EUA meeting, the FDA said the co - Benzinga
benzinga.com - May 11 at 2:20 PM
finance.yahoo.com logoWhy Veru Shares Are Soaring Today Premarket
finance.yahoo.com - May 11 at 2:20 PM
finance.yahoo.com logoFDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients - Yahoo Finance
finance.yahoo.com - May 11 at 8:34 AM
finance.yahoo.com logoFDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
finance.yahoo.com - May 11 at 8:34 AM
finance.yahoo.com logoVeru stock soars after FDA agrees COVID-19 treatment can be submitted for EUA application
finance.yahoo.com - May 11 at 8:34 AM
benzinga.com logoThe Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, - Benzinga
benzinga.com - May 9 at 2:55 PM
investorplace.com logoVeru Stock Could Face Difficulties If the Culper Research Report Is True - InvestorPlace
investorplace.com - May 9 at 2:55 PM
investorplace.com logoVeru Stock Could Face Difficulties If the Culper Research Report Is True
investorplace.com - May 9 at 10:02 AM
finance.yahoo.com logoVeru Inc. (VERU) Stock Moves -1.8%: What You Should Know
finance.yahoo.com - May 5 at 11:54 PM
finance.yahoo.com logoEarnings Preview: Veru Inc. (VERU) Q2 Earnings Expected to Decline
finance.yahoo.com - May 5 at 6:54 PM
finance.yahoo.com logoBioMed Momentum: NMLSF, BBI, LMLLF, VERU; Life Sciences Leaders Report Latest Advances in New Drug Development for Autism, COVID-19, Oncology, and Glaucoma - Yahoo Finance
finance.yahoo.com - May 4 at 8:47 PM
globenewswire.com logoBioMed Momentum: NMLSF, BBI, LMLLF, VERU; Life Sciences Leaders Report Latest Advances in New Drug Development for Autism, COVID-19, Oncology, and Glaucoma - GlobeNewswire
globenewswire.com - May 4 at 3:47 PM
finance.yahoo.com logoFDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study - Yahoo Finance
finance.yahoo.com - May 2 at 7:59 PM
fool.com logoWhy Veru Stock Plummeted on Monday - The Motley Fool
fool.com - May 2 at 7:59 PM
finance.yahoo.com logoWhy Veru Stock Plummeted on Monday
finance.yahoo.com - May 2 at 7:59 PM
seekingalpha.com logoVeru gains after FDA grants pre-emergency use nod meeting date for COVID drug sabizabulin - Seeking Alpha
seekingalpha.com - May 2 at 9:40 AM
globenewswire.com logoFDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study - GlobeNewswire
globenewswire.com - May 2 at 9:40 AM
finance.yahoo.com logoFDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study
finance.yahoo.com - May 2 at 9:40 AM
finance.yahoo.com logoVeru to Report Fiscal 2022 Second-Quarter Financial Results, Host Conference Call on May 12th - Yahoo Finance
finance.yahoo.com - April 29 at 1:21 AM
Get Veru News Delivered to You Automatically

Sign up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.